NCT05287945View on ClinicalTrials.gov

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

August 31, 2025

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Orellanine

Orellanine administered intravenously

Trial Locations (1)

Unknown

RECRUITING

Karolinska University Hospital, Stockholm

Sponsors

Lead Sponsor

Oncorena AB
All Listed Sponsors
lead

Oncorena AB

INDUSTRY

NCT05287945 - Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter